ITM launches study on a preventative drug for HIV
Antwerp’s Institute for Tropical Medicine is launching Flanders’ first study on the use of a drug that prevents HIV infection
200 men needed
PrEP, short for pre-exposure prophylaxis, is a pill with HIV inhibitors meant for temporary use by people who don’t have HIV but are at a high risk of infection. The project will examine if gay men are willing to use PrEP, how conscientiously the pills are taken, how the use of PrEP is experienced and whether the use of condoms is altered.
“PrEP is a promising medication, but the consequences have to be examined closely before the strategy can be introduced in our country,” said professor Marie Laga, co-ordinator of Be-PrEP-ared.
Every day, there are three new HIV diagnoses in Belgium, mainly among gay men and residents with origins in Sub-Saharan Africa. Among Belgian men, more than 80% of new infections are transmitted via sexual contact.
Two hundred men are needed for the ITM study and can apply for consideration to be part of the study until 24 September. The study is being carried out with support of the Flemish government’s Agency for Innovation in Science and Technology and in collaboration with relevant partners such as sexual health centre Sensoa and LGBT rights organisation Cavaria.
Photo: An HIV-infected cell
Photo courtesy NIAID / Flickr
Institute of Tropical Medicine
institute was founded
medical consultations per year